LDR vs. HDR Brachytherapy for Prostate Cancer

Conditions de participation

• Sexe:

  MALE

• Âges admissibles:

  40 to 80

Critères de participation

Inclusion Criteria:

Favorable risk and low-tier intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.

* Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8
* ECOG 0-1
* Low tier intermediate-risk prostate cancer is defined by a single NCCN intermediate risk factor
* Extensive favorable-risk disease is defined as:

* clinical stage T1c-T2a
* PSA \< 10
* Gleason 6
* ≥ 50% of biopsy cores containing cancer
* PSA density \> 0.2 ng/cc
* Selected intermediate risk patients not defined above

* - T1c/T2a
* - PSA \< 10
* -Gleason 4+3
* -\< 33% of cores involved
* -Max tumor length in any core 10 mm
* No androgen deprivation therapy (ADT)
* Prostate volume by TRUS ≤ 60 cc.
* Not eligible for, or accepting of, active surveillance according to NCCN guidelines.
* Signed study specific informed consent.

Exclusion Criteria:

* Prior radical surgery for carcinoma of the prostate,
* Prior pelvic radiation
* Prior chemotherapy for prostate cancer,
* Prior TURP or cryosurgery of the prostate
* Claustrophobic or unable to undergo MRI